Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of
patients with recurrent Ta and T1 who experienced treatment failure with at least one prior
BCG intravesical treatment.